News

In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.

New open-label extension data support the long-term use of the systemic therapy in patients with moderate-to-severe disease.

The study results are consistent with previous meta-analyses that show the efficacy of FMT in patients with IBD compared to placebo.

Bezlotoxumab is a fully humanized monoclonal antibody approved by the US Food and Drug Administration in 2017 for the prevention of recurrent CDI.

Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.

Real-world analysis comparing systemic therapies show dupilumab better improves EASI and quality of life among affected children.

Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.

Data from the ongoing TARGET-DERM AM observational study show patients with more exposed disease have generally worse severity and challenges linked to quality of life.

The recent GUIDE study examined the efficacy of guselkumab for moderate-to-severe plaque psoriasis, finding it consistent with previous trials.

The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in chilren and adolescents.

The novel OX40 inhibitor showed significant efficacy in 4 different doses versus placebo in Fall Clinical Dermatology data.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Recent phase 3 trial results suggest positive effects and faster onset using CAL/BDP cream for adult plaque psoriasis.

Pooled data from 7 clinical trials show the IL-23 inhibitor is not associated with worsened risk of adverse events or infections.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Dermatologists and primary care physicians believe there is a significant unmet need for treatments for patients with mild or moderate atopic dermatitis.

Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.

A discussion regarding the use of plaque psoriasis treatments such as apremilast, ixekizumab, and methotrexate.

A dermatologist considers what the orally-administered TYK2 inhibitor will provide eligible adult patients.

Data from the phase 3 LIMMitless show patients received long-term benefit from the biologic, regardless of baseline demographic or disease status.

Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.

Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.

Data from NORD Breakthrough Summit 2022 support the need for exacerbation prevention among patients with bronchiectasis, a rare chronic condition.

The monitoring strategy used a self-operated artificial-intelligence–enabled home monitoring system in conjunction with standard care for early detection of nAMD.

The findings indicate a discrepancy between racial and ethnic demographic data in RCTs of DME and RVO and the 2010 US Census population.

Risk factors associated with inpatient mortality, included increasing age, ulcerative colitis, IBD-related surgery, pneumonia, chronic lung disease, acute kidney injury, malnutrition, frailty, heart failure, blood transfusion, sepsis/septic shock, and thromboembolism.